June 10, 2022

Dosing more than Skin Deep: A Transdermal Drug Delivery Platform from Dyve Biosciences

Dosing more than Skin Deep: A Transdermal Drug Delivery Platform from Dyve Biosciences

There’s nothing new about transdermal delivery of drugs—patches, gadgets, and solvents abound—but each has physical limitations, and the drugs themselves may not be amenable to a particular approach. Enter a novel drug formulation platform by Dyve Biosciences. Delivered in what appears to be a cosmetic cream, Dyve has two POC clinical trials underway: Gout, to test local delivery of a drug; and cancer, testing the same drug that can only be delivered through the skin, and targeting the tumor microenvironment (with a buy-in from Moffitt Cancer Center). CEO Dr. Ryan Beal explains…